Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1961 1
1963 1
1965 2
1966 2
1967 1
1968 8
1969 3
1970 1
1971 8
1972 4
1973 4
1974 3
1975 1
1976 4
1977 1
1978 4
1979 6
1980 3
1981 6
1982 4
1983 8
1984 7
1985 5
1986 9
1987 9
1988 4
1989 11
1990 8
1991 9
1992 5
1993 11
1994 8
1995 11
1996 9
1997 17
1998 15
1999 21
2000 31
2001 29
2002 7
2003 12
2004 15
2005 13
2006 16
2007 23
2008 33
2009 36
2010 34
2011 37
2012 43
2013 34
2014 41
2015 33
2016 31
2017 22
2018 17
2019 25
2020 33
2021 35
2022 33
2023 26
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

826 results

Results by year

Filters applied: . Clear all
Page 1
Pulse-driven self-reconfigurable meta-antennas.
Ushikoshi D, Higashiura R, Tachi K, Fathnan AA, Mahmood S, Takeshita H, Homma H, Akram MR, Vellucci S, Lee J, Toscano A, Bilotti F, Christopoulos C, Wakatsuchi H. Ushikoshi D, et al. Among authors: takeshita h. Nat Commun. 2023 Feb 6;14(1):633. doi: 10.1038/s41467-023-36342-1. Nat Commun. 2023. PMID: 36746941 Free PMC article.
Pembrolizumab plus enfortumab vedotin in urothelial cancer.
Santoni M, Takeshita H, Massari F, Bamias A, Cerbone L, Fiala O, Mollica V, Buti S, Santoni A, Bellmunt J. Santoni M, et al. Among authors: takeshita h. Nat Rev Urol. 2024 Jan 24. doi: 10.1038/s41585-024-00858-y. Online ahead of print. Nat Rev Urol. 2024. PMID: 38267716 No abstract available.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Cattrini C, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchenhorn D, Santini D, Manneh R, Bisonni R, Zakopoulou R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Sorgentoni G, Battelli N, Porta C, Bellmunt J, Santoni M. Fiala O, et al. Among authors: takeshita h. Cancer Immunol Immunother. 2023 Nov;72(11):3665-3682. doi: 10.1007/s00262-023-03518-z. Epub 2023 Sep 7. Cancer Immunol Immunother. 2023. PMID: 37676282
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabrò F, Porta C. Santoni M, et al. Among authors: takeshita h. Cancer Immunol Immunother. 2023 Sep;72(9):2961-2970. doi: 10.1007/s00262-023-03469-5. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37248424
Comparative biochemical properties of vertebrate deoxyribonuclease I.
Fujihara J, Yasuda T, Ueki M, Iida R, Takeshita H. Fujihara J, et al. Among authors: takeshita h. Comp Biochem Physiol B Biochem Mol Biol. 2012 Nov-Dec;163(3-4):263-73. doi: 10.1016/j.cbpb.2012.07.002. Epub 2012 Aug 3. Comp Biochem Physiol B Biochem Mol Biol. 2012. PMID: 22885404 Review.
Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers.
Kawaguchi T, Komatsu S, Ichikawa D, Tsujiura M, Takeshita H, Hirajima S, Miyamae M, Okajima W, Ohashi T, Imamura T, Kiuchi J, Konishi H, Shiozaki A, Okamoto K, Otsuji E. Kawaguchi T, et al. Among authors: takeshita h. Int J Mol Sci. 2016 Sep 1;17(9):1459. doi: 10.3390/ijms17091459. Int J Mol Sci. 2016. PMID: 27598137 Free PMC article. Review.
826 results